PTC Therapeutics, Inc. Equity Securities, FV-NI, Unrealized Gain (Loss)
PTC Therapeutics, Inc. (PTCT) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of $1.91 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2026-07-30
- PTC Therapeutics, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-06-30 was $700.00K, a 8.38% decline year-over-year.
- PTC Therapeutics, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-03-31 was $1.21M, a 56.85% increase year-over-year.
- PTC Therapeutics, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-12-31 was $800.00K, a 23.27% increase year-over-year.
- PTC Therapeutics, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-09-30 was $1.62M, a 99.75% increase year-over-year.
- PTC Therapeutics, Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2025 was $3.96M, a 53.97% increase from fiscal 2024.
- PTC Therapeutics, Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2024 was $2.57M, a 2.19% increase from fiscal 2023.
- PTC Therapeutics, Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2023 was $2.52M.
- PTC Therapeutics, Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2022 was -$7.99M, a 577.70% decline from fiscal 2021.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $1.91M 10-Q · filed 2026-07-30 | $2.71M derived: sum of 3 quarters · filed 2026-07-30 | $4.34M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $1.21M 10-Q · filed 2026-05-07 | $2.01M derived: sum of 2 quarters · filed 2026-05-07 | $3.64M derived: sum of 3 quarters · filed 2026-05-07 | $4.40M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $2.42M derived: sum of 2 quarters · filed 2026-02-19 | $3.19M derived: sum of 3 quarters · filed 2026-07-30 | $3.96M 10-K · filed 2026-02-19 |
| 2025-09-30 | $1.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $2.39M derived: sum of 2 quarters · filed 2026-07-30 | $3.16M 10-Q · filed 2025-11-04 | $3.81M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $764.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $1.54M 10-Q · filed 2026-07-30 | $2.19M derived: sum of 3 quarters · filed 2026-07-30 | $3.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $774.00K 10-Q · filed 2026-05-07 | $1.42M derived: sum of 2 quarters · filed 2026-05-07 | $2.23M derived: sum of 3 quarters · filed 2026-05-07 | $2.64M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $649.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $1.46M derived: sum of 2 quarters · filed 2026-02-19 | $1.86M derived: sum of 3 quarters · filed 2026-02-19 | $2.57M 10-K · filed 2026-02-19 |
| 2024-09-30 | $812.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.21M derived: sum of 2 quarters · filed 2025-11-04 | $1.92M 10-Q · filed 2025-11-04 | -$1.04M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $401.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.11M 10-Q · filed 2025-08-07 | -$1.86M derived: sum of 3 quarters · filed 2026-02-19 | -$736.00K derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $710.00K 10-Q · filed 2025-05-06 | -$2.26M derived: sum of 2 quarters · filed 2026-02-19 | -$1.14M derived: sum of 3 quarters · filed 2026-02-19 | $1.06M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | -$2.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$1.85M derived: sum of 2 quarters · filed 2026-02-19 | $351.00K derived: sum of 3 quarters · filed 2026-02-19 | $2.52M 10-K · filed 2026-02-19 |
| 2023-09-30 | $1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $3.32M derived: sum of 2 quarters · filed 2024-11-07 | $5.48M 10-Q · filed 2024-11-07 | $8.81M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $2.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $4.36M 10-Q · filed 2024-08-08 | $7.69M derived: sum of 3 quarters · filed 2025-02-27 | $7.73M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $2.17M 10-Q · filed 2024-04-25 | $5.49M derived: sum of 2 quarters · filed 2025-02-27 | $5.53M derived: sum of 3 quarters · filed 2025-02-27 | $651.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $3.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.36M derived: sum of 2 quarters · filed 2025-02-27 | -$1.51M derived: sum of 3 quarters · filed 2025-02-27 | -$7.99M 10-K · filed 2025-02-27 |
| 2022-09-30 | $37.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | -$4.84M derived: sum of 2 quarters · filed 2023-10-26 | -$11.32M 10-Q · filed 2023-10-26 | -$11.00M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$4.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$11.36M 10-Q · filed 2023-08-03 | -$11.03M derived: sum of 3 quarters · filed 2024-02-29 | -$10.38M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$6.48M 10-Q · filed 2023-04-27 | -$6.15M derived: sum of 2 quarters · filed 2024-02-29 | -$5.50M derived: sum of 3 quarters · filed 2024-02-29 | -$4.50M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $323.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $979.00K derived: sum of 2 quarters · filed 2024-02-29 | $1.98M derived: sum of 3 quarters · filed 2024-02-29 | $1.67M 10-K · filed 2024-02-29 |
| 2021-09-30 | $656.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $1.66M derived: sum of 2 quarters · filed 2022-10-27 | $1.35M 10-Q · filed 2022-10-27 | |
| 2021-06-30 | $1.00M 10-Q · filed 2021-07-29 | $694.00K 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | -$302.00K 10-Q · filed 2022-05-03 | |||
| 2020-12-31 | $14.31M 10-K · filed 2021-02-25 | |||
| 2019-12-31 | $2.19M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |